Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Rossana, Casaretti"'
Autor:
Maddalena Leongito, Raffaele Palaia, Rossana Casaretti, Fabiana Tatangelo, Francesca Foschini, Annabella Di Mauro, Andrea Belli, Vittorio Albino
Publikováno v:
Clinical Case Reports, Vol 11, Iss 6, Pp n/a-n/a (2023)
The esophagus undergoes shrinkage after resection and fixation. The surgical in situ margin is greater than the specimen margin, measured by the pathologist. The length of disease‐free margins is critical to therapeutic planning. We propose specime
Externí odkaz:
https://doaj.org/article/9059b4a692da419ba04e2033b8b5f776
Autor:
Alfonso De Stefano, Nicoletta Zanaletti, Antonino Cassata, Lucrezia Silvestro, Anna Nappi, Rossana Casaretti, Carmela Romano, Francesca Foschini, Claudia Cardone, Marco Borrelli, Antonella Petrillo, Alfredo Budillon, Paolo Delrio, Antonio Avallone
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundMetastatic colorectal cancer is one of the most common causes of cancer death worldwide. RAS and BRAF mutational analyses are strongly recommended before beginning chemotherapy in the metastatic setting for their predictive role for the eff
Externí odkaz:
https://doaj.org/article/3a3e503e911d4621923e51f1fbf60f81
Autor:
Alessandro Ottaiano, Stefania Scala, Nicola Normanno, Maria Napolitano, Monica Capozzi, Anna Maria Rachiglio, Cristin Roma, Anna Maria Trotta, Crescenzo D’Alterio, Luigi Portella, Carmela Romano, Antonino Cassata, Rossana Casaretti, Lucrezia Silvestro, Anna Nappi, Salvatore Tafuto, Antonio Avallone, Alfonso De Stefano, Mario Tamburini, Carmine Picone, Antonella Petrillo, Francesco Izzo, Raffaele Palaia, Vittorio Albino, Alfonso Amore, Andrea Belli, Ugo Pace, Massimiliano Di Marzo, Paolo Chiodini, Gerardo Botti, Gianfranco De Feo, Paolo Delrio, Guglielmo Nasti
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC). However,
Externí odkaz:
https://doaj.org/article/c63b96d6390c4ab8b86f568154c6b5fd
Autor:
Antonio Avallone, Maria Carmela Piccirillo, Elena Di Gennaro, Carmela Romano, Filomena Calabrese, Maria Serena Roca, Fabiana Tatangelo, Vincenza Granata, Antonio Cassata, Ernesta Cavalcanti, Nicola Maurea, Piera Maiolino, Lucrezia Silvestro, Alfonso De Stefano, Francesco Giuliani, Gerardo Rosati, Emiliano Tamburini, Pasquale Aprea, Valeria Vicario, Anna Nappi, Carlo Vitagliano, Rossana Casaretti, Alessandra Leone, Antonella Petrillo, Gerardo Botti, Paolo Delrio, Francesco Izzo, Francesco Perrone, Alfredo Budillon
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in RAS -mutated tumors, thus suggesting the need for novel combinatorial therapies. Epigenetic alterations play an important role in initiat
Externí odkaz:
https://doaj.org/article/3eb026fee6a04fa2a16807978c679bff
Autor:
Stefania Scala, Rosario Vincenzo Iaffaioli, Daniela Califano, Antonio Avallone, Crescenzo D'Alterio, Rossana Casaretti, Serena Zanotta, Maria Napolitano, Chiara De Divitiis, Anna Nappi, Guglielmo Nasti, Carmela Romano, Alessandro Ottaiano, Anna Maria Trotta
Cetuximab is a monoclonal antibody to the EGFR that induces antibody-dependent cell cytotoxicity (ADCC) through Fcγ receptors on immune cells. Although SNPs in genes encoding Fcγ receptors are functionally relevant to cetuximab-mediated ADCC in col
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14e6a9a179d4116f4059c59768616527
https://doi.org/10.1158/2326-6066.c.6548848
https://doi.org/10.1158/2326-6066.c.6548848
Autor:
Stefania Scala, Rosario Vincenzo Iaffaioli, Daniela Califano, Antonio Avallone, Crescenzo D'Alterio, Rossana Casaretti, Serena Zanotta, Maria Napolitano, Chiara De Divitiis, Anna Nappi, Guglielmo Nasti, Carmela Romano, Alessandro Ottaiano, Anna Maria Trotta
Progression-free survival was defined as time elapsed between treatment initiation and clinical progression. PFS was 10.8 months in patients whit FcγRIIIa-V158F or FcγRIIIa-V158V vs 5.1 months in patients whit FcγRIIIa-F158F. Log-Rank test for two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f93a3a4db07f2ea0bae49e9c9bef29a
https://doi.org/10.1158/2326-6066.22538656.v1
https://doi.org/10.1158/2326-6066.22538656.v1
Autor:
Monica Capozzi, Chiara De Divitiis, Alessandro Ottaiano, Tramontano Teresa, Maurizio Capuozzo, Piera Maiolino, Gerardo Botti, Salvatore Tafuto, Antonio Avallone, The Abdominal Oncology Group, Rossana Casaretti, Antonino Cassata, Anna Nappi, Guglielmo Nasti, Carmela Romano, Lucrezia Silvestro
Publikováno v:
Frontiers in Public Health, Vol 6 (2018)
Introduction: The therapeutic scenario of Oncology is enriching of innovative agents which are determining an increase in public expenditure because of their high cost. In Italy, a web-based government Registry is used to monitor the clinical use of
Externí odkaz:
https://doaj.org/article/1557ec5b7d5141938c131ba3de255fcb
Autor:
Alessandro Ottaiano, Alfonso De Stefano, Monica Capozzi, Anna Nappi, Chiara De Divitiis, Carmela Romano, Lucrezia Silvestro, Antonino Cassata, Rossana Casaretti, Salvatore Tafuto, Michele Caraglia, Massimiliano Berretta, Guglielmo Nasti, Antonio Avallone
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Introduction: We performed a meta-analysis in order to analyze and quantify the effect on survival of starting therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients with anti-EGFR agents or bevacizumab.Patients and Methods: Rando
Externí odkaz:
https://doaj.org/article/89295854267f4a9ca4ccd1533b09a53c
Autor:
Gerardo Rosati, Chiara Alessandra Cella, Luigi Cavanna, Carla Codecà, Michele Prisciandaro, Stefania Mosconi, Giovanna Luchena, Nicola Silvestris, Ilaria Bernardini, Rossana Casaretti, Federica Zoratto, Domenico Amoroso, Andrea Ciarlo, Sandro Barni, Stefano Cascinu, Cristina Davite, Alessandro Di Sanzo, Alessia Casolaro, Domenico Bilancia, Roberto Labianca
Publikováno v:
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 25(4)
EOX (epirubicin, oxaliplatin, and capecitabine) is one of the standard regimens for metastatic or locally advanced gastric cancer (GC). A new combination based on fractional docetaxel (low-TOX) has been developed in an attempt to increase the efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5da648de263efafc6a862d274cd1e4a1
https://pubmed.ncbi.nlm.nih.gov/35352176
https://pubmed.ncbi.nlm.nih.gov/35352176
Autor:
Francesco Izzo, Anna Maria Trotta, Vittorio Albino, Lucrezia Silvestro, Antonio Avallone, Raffaele Palaia, Gerardo Botti, Monica Capozzi, Paolo Chiodini, Rossana Casaretti, Carmine Picone, Stefania Scala, Nicola Normanno, Mario Tamburini, Andrea Belli, Crescenzo D'Alterio, Anna Maria Rachiglio, Massimiliano Di Marzo, Guglielmo Nasti, Paolo Delrio, Cristin Roma, Anna Nappi, Carmela Romano, Antonella Petrillo, Antonino Cassata, Gianfranco De Feo, Alessandro Ottaiano, Salvatore Tafuto, Maria Napolitano, Alfonso Amore, Alfonso De Stefano, Ugo Pace, Luigi Portella
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
BMC Cancer
Background Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC). However, patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c43cfe009a23eb43b3a59b261dce1259
http://link.springer.com/article/10.1186/s12885-019-6109-z
http://link.springer.com/article/10.1186/s12885-019-6109-z